Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Key Business Regulations to Consider While Arranging Your Independent venture - 2Some Americans say they'll go without health insurance as ACA rates spike
- 3Fundamental Home Machines: An Easy to understand Determination Guide
- 4Shelby County deputies charged with assault, placed on leave
- 5‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- Oldest evidence of human fire-making discovered at site in England
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- High Court freezes government move to shutter Army Radio pending ruling
- A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
- IDF Givati Brigade soldier arrested, charged in suspected Iran espionage
- Little Italy Mercato brings fresh food and community to downtown San Diego
- The Main 20 Gaming Control center Ever
- Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients
